Literature DB >> 25065853

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

Ho-June Lee1, Guanglei Zhuang1, Yi Cao2, Pan Du2, Hyo-Jin Kim1, Jeff Settleman3.   

Abstract

Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells. We found that many drug-treated "oncogene-addicted" cancer cells engage a positive feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response. This was observed in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS. Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacological inhibition of MEK together with JAK and FGFR enhanced tumor regression. These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25065853     DOI: 10.1016/j.ccr.2014.05.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  239 in total

Review 1.  Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.

Authors:  Nikolas Balanis; Cathleen R Carlin
Journal:  Mol Cell Endocrinol       Date:  2017-01-12       Impact factor: 4.102

2.  1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.

Authors:  Marwa Ali A Fathi; Amer Ali Abd El-Hafeez; Dalia Abdelhamid; Samar H Abbas; Monica M Montano; Mohamed Abdel-Aziz
Journal:  Bioorg Chem       Date:  2018-11-22       Impact factor: 5.275

3.  Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells.

Authors:  Azadeh Arabzadeh; Jeremy Dupaul-Chicoine; Valérie Breton; Sina Haftchenary; Sara Yumeen; Claire Turbide; Maya Saleh; Kevin McGregor; Celia M T Greenwood; Uri David Akavia; Richard S Blumberg; Patrick T Gunning; Nicole Beauchemin
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

4.  Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.

Authors:  Veronica Lifshitz; Saul J Priceman; Wenzhao Li; Gregory Cherryholmes; Heehyoung Lee; Adar Makovski-Silverstein; Lucia Borriello; Yves A DeClerck; Hua Yu
Journal:  Mol Cancer Ther       Date:  2017-07-17       Impact factor: 6.261

5.  RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.

Authors:  Bruno Bockorny; Maria Rusan; Wankun Chen; Rachel G Liao; Yvonne Li; Federica Piccioni; Jun Wang; Li Tan; Aaron R Thorner; Tianxia Li; Yanxi Zhang; Changhong Miao; Therese Ovesen; Geoffrey I Shapiro; David J Kwiatkowski; Nathanael S Gray; Matthew Meyerson; Peter S Hammerman; Adam J Bass
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

Review 6.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

7.  G3BP1 and G3BP2 regulate translation of interferon-stimulated genes: IFITM1, IFITM2 and IFITM3 in the cancer cell line MCF7.

Authors:  Umber Alam; Derek Kennedy
Journal:  Mol Cell Biochem       Date:  2019-06-06       Impact factor: 3.396

8.  JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Authors:  Kazuhiko Shien; Vassiliki A Papadimitrakopoulou; Dennis Ruder; Carmen Behrens; Li Shen; Neda Kalhor; Juhee Song; J Jack Lee; Jing Wang; Ximing Tang; Roy S Herbst; Shinichi Toyooka; Luc Girard; John D Minna; Jonathan M Kurie; Ignacio I Wistuba; Julie G Izzo
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

9.  JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

Authors:  Kian Kani; Carolina Garri; Katrin Tiemann; Paymaneh D Malihi; Vasu Punj; Anthony L Nguyen; Janet Lee; Lindsey D Hughes; Ruth M Alvarez; Damien M Wood; Ah Young Joo; Jonathan E Katz; David B Agus; Parag Mallick
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

10.  STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.

Authors:  Elisabet Cuyàs; Almudena Pérez-Sánchez; Vicente Micol; Javier A Menendez; Joaquim Bosch-Barrera
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.